It's been a rocky road for hepatitis C drugmaker Idenix Pharmaceuticals (NASDAQ: IDIX ) , but investors are smiling after Merck (NYSE: MRK ) announced on Monday that it's buying the biotech for $3.85 billion, more than a 230% premium on Friday's closing price. Even investors who bought at the previous top a few years ago when investors had high hopes that every hepatitis C biotech was going to get bought still had a profitable ending.
Fellow hepatitis C drugmaker Achillion (NASDAQ: ACHN ) was up big yesterday, with investors hoping that it'll get bought out as well, but investors should be careful here; there are diminishing potential returns as each hepatitis C drugmaker gets picked off. With Merck now owning Idenix Pharmaceuticals, there's one less company that might want to purchase Achillion.
Gilead Sciences (NASDAQ: GILD ) traded down, presumably because investors are worried that Merck will become a stronger competitor with Idenix's assets, but there is upside for Gilead Sciences' investors: Merck's purchase is a sign that the pharma thinks there will be plenty of patients a few years from now, when Idenix Pharmaceuticals' drugs could make it to market.
Watch the following video for thoughts on the deal from senior biotech specialist Brian Orelli and health-care analyst David Williamson, including the potential wildcard: patents.
Not a biotech, but this stock has multi-bagger potential
Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.